Drug
Ammonium trichloro(dioxoethylene-O,O'-)tellurate clinical trials
Also written AS-101.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2015 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
BioMAS Ltd (6) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Feramda (1) · Rabin Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ammonium trichloro(dioxoethylene-O,O'-)tellurate is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001006Written as AS-101
- Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)CompletedPhase 1/2FeramdaNCT03216538Written as AS101 1% oral solution
- Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital WartsStatus unknownPhase 2BioMAS LtdNCT01943630Written as 15% AS101 gel
- Topical Application of AS101 for the Treatment of PsoriasisWithdrawnPhase 2BioMAS LtdNCT00788424Written as AS101 Cream
- Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) PatientsSuspendedPhase 2BioMAS LtdNCT01010373Written as AS101
- Topical Application of AS101 for the Treatment of Atopic DermatitisTerminatedPhase 2BioMAS LtdNCT00927212Written as AS101 ointment
- Safety and Efficacy Study to Test Topical AS101 for External Genital WartsCompletedPhase 1/2BioMAS LtdNCT01555112Written as Topical AS101
- Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor PatientsTerminatedPhase 2BioMAS LtdNCT00926354Written as AS101
- Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause WomenStatus unknownPhase 2Rabin Medical CenterNCT00418249Written as AS101
- An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC PatientsCompletedNot applicableWyeth is now a wholly owned subsidiary of PfizerNCT00002266Written as AS-101
- A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC PatientsCompletedNot applicableWyeth is now a wholly owned subsidiary of PfizerNCT00002013Written as AS-101
- A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced DiseaseCompletedNot applicableWyeth is now a wholly owned subsidiary of PfizerNCT00002033Written as AS-101
Codes
What other systems call ammonium trichloro(dioxoethylene-O,O'-)tellurate · ClinicalTrials.gg INT003353
- MeSH (NLM) C054105ammonium trichloro(dioxoethylene-O,O'-)tellurateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 708681952AAMMONIUM TRICHLOROTELLURATEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C054105 | ammonium trichloro(dioxoethylene-O,O'-)tellurate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 708681952A | AMMONIUM TRICHLOROTELLURATE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.